EU/3/09/719: Orphan designation for the treatment of polycythaemia vera

Givinostat

Table of contents

Overview

On 3 February 2010, orphan designation (EU/3/09/719) was granted by the European Commission to Italfarmaco S.p.A., Italy, for givinostat for the treatment of polycythaemia vera.

Key facts

Active substance
Givinostat
Intended use
Treatment of polycythaemia vera
Orphan designation status
Positive
EU designation number
EU/3/09/719
Date of designation
03/02/2010
Sponsor

Italfarmaco S.p.A.
Viale Fulvio Testi 330
20126 Milan
MI
Italy
E-mail: info@italfarmaco.com

Update history

DateUpdate
August 2023The sponsor’s address was updated in August 2023.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating